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Abstract
The aims of this work were to evaluate whether the treatment of patients with fibromyalgia with memantine is associated
with significant changes in metabolite concentrations in the brain, and to explore any changes in clinical outcome measures.
Magnetic resonance spectroscopy was performed of the right anterior and posterior insula, both hippocampi and the
posterior cingulate cortex. Questionnaires on pain, anxiety, depression, global function, quality of life and cognitive impair-
ment were used. Ten patients were studied at baseline and after three months of treatment with memantine. Significant
increases were observed in the following areas: N-acetylaspartate (4.47 at baseline vs. 4.71 at three months, p¼ 0.02) and
N-acetylaspartateþN-acetylaspartate glutamate in the left hippocampus (5.89 vs. 5.98; p¼ 0.007); N-acetylaspartateþ
N-acetylaspartate glutamate in the right hippocampus (5.31 vs 5.79; p¼ 0.01) and the anterior insula (7.56 vs. 7.70;
p¼ 0.033); glutamateþglutamine/creatine ratio in the anterior insula (2.03 vs. 2.17; p¼ 0.022) and the posterior insula
(1.77 vs. 2.00; p¼ 0.004); choline/creatine ratio in the posterior cingulate (0.18 vs. 0.19; p¼ 0.023); and creatine in the right
hippocampus (3.60 vs. 3.85; p¼ 0.007). At the three-month follow-up, memantine improved cognitive function assessed by
the Cognition Mini-Exam (31.50, SD¼ 2.95 vs. 34.40, SD¼ 0.6; p¼ 0.005), depression measured by the Hamilton Depression
Scale (7.70, SD¼ 0.81 vs. 7.56, SD¼ 0.68; p¼ 0.042) and severity of illness measured by the Clinical Global Impression
severity scale (5.79, SD¼ 0.96 vs. 5.31, SD¼ 1.12; p¼ 0.007). Depression, clinical global impression and cognitive function
showed improvement with memantine. Magnetic resonance spectroscopy could be useful in monitoring response to the
pharmacological treatment of fibromyalgia.
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Introduction
Fibromyalgia (FM) is a chronic rheumatic condition of
currently unknown aetiology that is characterised by
the presence of diffuse musculoskeletal pain and painful
sensitivity to touch in at least 11/18 defined tender
points.1,2 FM is one of the main health problems pres-
ently affecting Western countries because of its high
prevalence, the clinical impact of patient disability
and diminished quality of life and the significant
health-care costs it produces3 It is currently accepted
that FM treatments have limited efficacy, with an
effect size of approximately 0.5.4
Pain is the most common and debilitating symptom
of FM. Although the aetiological factors of the disease
are not precisely known, the primary hypothesis on the
pathogenesis of FM highlights the role of the central
nervous system (CNS) in the amplification of pain per-
ception (i.e. central sensitisation) and in the
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development of other co-morbid symptoms (originating
in the CNS), such as sleep-related problems, fatigue,
cognitive difficulties and emotional distress.5–7
Similarly, various studies have also reported reduced
levels of certain neurotransmitters involved in the regu-
lation of the descending analgesic response (i.e. sero-
tonin and noradrenaline)8 and increased levels of
glutamate (Glu) and substance P. These abnormal
levels of brain metabolites seem to be associated with
increases in the pain response, facilitating hyperalgesia
and allodynia, both characteristics of FM.9
In recent years, the neurophysiology of the pain pro-
cess has led to increased interest in identifying the brain
structures activated when patients experience pain
through the use of different neuroimaging methods,
such as positron emission tomography (PET),10 single
photon emission computed tomography (SPECT),11,12
functional magnetic resonance imaging (fMRI) and,
more recently, magnetic resonance diffusion tensor
and volumetry.13
Proton magnetic resonance spectroscopy (1H-MRS)
is one of the techniques used to assess potential disrup-
tions of neuronal integrity and associated neurochemical
dysregulations. MRS provides additional biochemical
information which can be useful in determining the clin-
ical stratification for a specific patient.14–18
NMDA receptor antagonists have neuroprotective
properties that are important for pain reduction and
are widely used in clinical practice. Dextromethorphan
and ketamine have demonstrated efficacy in treating
the pain of FM,19,20 although their long-term use
shows significant limitations. Memantine, an NMDA
receptor antagonist, is a non-competitive open-channel
blocker that dissociates from the channel – a property
that allows it to limit the pathological activity of the
NMDA receptor without affecting normal synaptic
activity.21
Memantine has shown a very low incidence of
side effects in human clinical trials,22,23 while a recent
extension of trials has demonstrated the drug’s clinical
tolerability, even with prolonged use.24 The clinically
approved dose of memantine for humans starts at
5mg/day, increasing progressively over the span of
several weeks up to 20mg/day. This progressive dose
adjustment may contribute to the drug’s lack of side
effects.22 Although this reduces NMDA receptor affin-
ity, it contributes to the safety and efficacy of meman-
tine as a neuroprotective agent. This quality, however,
also makes memantine less effective for the treatment of
chronic pain than high-affinity antagonists (e.g. keta-
mine).25 Nevertheless, recent research has highlighted
the efficacy of memantine for the treatment of complex
regional pain syndrome26 and phantom limb pain,27
which suggests that the quality of pain reduction
depends on the type of pain being treated.
The aim of this study was to determine whether
a three-month treatment of patients with FM with
memantine is associated with significant changes in
concentrations of metabolites – N-acetylaspartate
(NAA), N-acetylaspartate glutamate (NAAG) and cre-
atine (Cr) – and metabolite ratios – glutamateþglutam-
ine/creatine (Glx/Cr) ratio and choline/creatine (Cho/
Cr) ratio – in the brain on MRS. The secondary aim
was to explore whether changes in clinical outcome
measures, such as cognitive performance, depression
score, anxiety score and quality of life, are associated
with the three-month treatment with memantine.
Methods
Patients
This was an open, uncontrolled, interventional, explora-
tory study with a three-month follow-up. Patients diag-
nosed with FM were recruited for inclusion in the study
from primary health-care centres in Zaragoza, Spain.
The patients were selected based on the following cri-
teria: age 18–65 years, Spanish comprehension skills
and diagnosed with FM by a rheumatologist certified
by the American College of Rheumatology. Additional
inclusion criteria1 were having the patient sign an
informed consent form and, for women, the use of
birth control during the study.
The intervention consisted of administering 20mg
memantine to 10 subjects. The treatment duration
was three months, including four weeks of dose adjust-
ment in which patients started with 5mg memantine in
the first week and increased the dose by 5mg each week
until the full dose was reached in the fourth week. The
20mg daily dosage continued for another two months.
Medications permitted during the trial were those listed
in the summary of product characteristics and the
patient information leaflet for memantine. No other
treatment for chronic pain was permitted. The study
variables were evaluated at the start of the trial (base-
line evaluation), at one month and at three months.
Imaging methods
MRI. The examinations were performed on a 1.5 T MRI
HD clinical scanner (GE Healthcare Diagnostic Imaging,
Milwaukee, WI). All of the images were acquired using
an eight-channel phased-array head coil in both transmit
and receive mode (NVHEAD A). All patients underwent
brain T1 and T2-weighted MRI.
MRS studies. MRS studies were performed with the
system automated single-voxel H1-MRS package
(PROBE/SV; GE Medical Systems). Localised
1H-MRS was performed using a short echo time (TE)
of 35ms, a repetition time (TR) of 2000ms and 128
accumulations using a single voxel with a spin echo
technique and selective excitation with gradient spoiling
for water suppression.
Five 8 cc (2 cm 2 cm 2 cm) spectra were acquired
on all patients, with automatic water suppression and
placement of saturation bands to suppress lipid con-
tamination. Spectra were rejected and repeated in the
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following cases: line width >8Hz, line shape asymmet-
rical after eddy current correction and the presence of
artifacts. The examinations were performed using a
coronal T2-weighted image (TR¼ 5350ms,
TE¼ 85ms, 90 flip angle, number of excitations¼ 2,
matrix size¼ 320 256, field of view¼ 24 cm 24 cm,
slice thickness/gap¼ 5/0mm) in the plane that goes
through inner auditive conducts. The brain peduncle
was used to locate volumes of interest (VOI; 2 cm
2 cm 2 cm) in both hippocampi. A midsagittal
T1-weighted image (TR¼ 560ms, TE¼ 12ms, 90 flip
angle, number of excitations¼ 1, matrix size¼ 256
160, field of view¼ 24 cm 24 cm, slice thickness/
gap¼ 5/0mm) was obtained to locate a voxel in the
posterior cingulate cortex (PCC). A line was drawn per-
pendicular to the splenium of the corpus callosum, and
another line was drawn oblique to the surface of the
corpus callosum. The intersection of the two lines
was positioned above the lower corner of the voxel
(Figure 1(a)). A parasagittal T1 image (TR¼ 560ms,
TE¼ 12ms, 90 flip angle, number of excitations¼ 1,
matrix size¼ 256 160, field of view¼ 24 cm 24 cm,
slice thickness/gap¼ 5/0mm) and 30mm on the right,
with respect to the plane of the corpus callosum. Since
the insula has a triangular shape, we always try to place
a voxel in the anterior and posterior insula. For the
insula, the anterior edge was aligned with the anteroin-
ferior insular pole in the axial plane; in the sagittal
plane, the midline of the voxel was aligned with the
Sylvian fissure, the posterior edge of the voxel aiming
at Heschel’s gyrus. The medial edge of the voxel was
aligned with the claustrum in the axial plane. The fol-
lowing exploration areas were chosen: (a) areas in
which the authors have found increased Glu levels pow-
ered by MRS,28–30 (b) brain structures that are acti-
vated during painful conditions in healthy control
group31 and in FM patients32 and (c) regions (men-
tioned in prior reports) that have been implicated in
cognitive impairment.33,34
The post processing of data was done with
LCModel v6.2-0 (Stephen Provencher, Oakville,
Canada),35 applying an eddy current correction and
using an internal water signal reference to calculate
the absolute metabolite concentrations. In addition to
the individual analysis of the Glu, Cr, NAA and myo-
inositol (mI) compounds, we also studied the summed
concentrations of the following three compound
pairs: NAAþNAAG, referred to as total NAA;
glycerophosphocholineþphosphocreatine (GPC), referred
to as total Cho; and glutamateþglutamine, referred to
as Glx (Figure 1(b)). The absolute metabolite values
were only considered when the Kramer–Rao lower
bound was <20%, thus indicating that these metabol-
ites could be reliably estimated.
Concentration values are not corrected for cerebral
spinal fluid contributions. We also obtained the abso-
lute concentrations of brain metabolites and the ratios
of the metabolites relative to Cr. In clinical practice,
Figure 1(a). Voxel placement. Sagittal and coronal T1-weighted magnetic resonance imaging with the voxel placed in the (a) posterior
cingulate gyrus; (b) anterior insula; (c) posterior insula; and (d) both hippocampi.
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metabolic ratios are assessed using Cr, which is con-
sidered the most stable metabolite, as an internal
reference.36
Secondary efficacy variables. The secondary efficacy
variables were modifications to the following clinical
variable values: pain threshold, pain perception, cogni-
tive state, health status, anxiety and depression levels
and quality of life. The variables were measured
and assessed according to the following tests. Pain
threshold was measured by a sphygmomanometer.37
Perceived pain was measured using a visual analogue
scale (VAS).38 Cognitive state was measured using
the Cognition Mini-Exam (MEC). In non-geriatric
populations (<65 years of age), such as the sample in
this study, 27 points is the threshold that suggests a
‘likely case’ of a cognitive disorder. The MEC test is the
validated Spanish-language version of the Mini-Mental
State Examination.39 FM health status was measured
with the Fibromyalgia Impact Questionnaire (FIQ).40
The validated Spanish-language version of this ques-
tionnaire was used.41 Anxiety and depression levels
were measured with the Hospital Anxiety Depression
Scale (HADS).42 Quality of life was measured with the
EuroQol 5D questionnaire.43 Severity of illness was
measured with the Clinical Global Impression (CGI)
scale, which is amongst the most widely used extant
brief assessment tools in psychiatry. The CGI is a
three-item observer-rated scale that measures severity
of illness, global improvement or change and thera-
peutic response.44
A small patient sample (N¼ 10) was chosen, as this
was an exploratory study. Similar sample sizes have
been used to identify significant differences in the
levels of metabolites in different brain regions of FM
patients and control groups.28–30
Statistics
To describe the quantitative variables, mean and
standard deviations were calculated when they fulfilled
normality criteria. The chi-square test was used for socio-
demographic and other qualitative variables. The differ-
ence between clinical variables at baseline, one month and
three months was calculated using an analysis of variance
for repeated measures. The difference between neuroima-
ging tests taken at baseline and at three months was ana-
lysed using Student’s t-test for paired measurements. The
relationship between the neuroimaging variables and the
clinical variables was calculated using a Spearman’s rho
non-parametric test. Statistical analyses were performed
using SPSS for Windows v15, with p-values< 0.05 con-
sidered significant. The difference of each metabolite was
calculated after treatment with memantine and was
Figure 1(b). Example of spectrum acquired with the LCModel software in the (a) posterior cingulate gyrus; (b) anterior insula;
(c) posterior insula; and (d) both hippocampi with the following peaks: mI: myo-inositol; Cho: choline compounds; Cr: creatine;
Glx: glutamateþglutamineþGABA; NAA: N-acetylaspartate.
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placed as a dependent variable in a linear regression
model after checking the normality of the new variables.
Changes in measuring instruments, pain, the HADS,
FIQ, MEC and CGI were included as independent
variables.
Ethics and consent
Informed consent was obtained from the participants
before they were aware of to which group they were
assigned. The study follows the Declaration of
Helsinki convention with posterior modifications as
well as the Declaration of Madrid of the World
Psychiatric Association. The study protocol was
approved by the Clinical Research Ethics Committee
of Arago´n (June 2012).
Results
The study patient sample showed the expected charac-
teristics of FM patients, including female predomin-
ance (100%), middle-aged (M¼ 46.82, SD¼ 5.34),
married (8/10), medium level of education (M¼ 8.44
years, SD¼ 2.16 years of education) and frequently dis-
abled (5/10) or on sick leave (1/10).
All the patients completed the study. Six patients
took the recommended doses (20mg/day), two
reached 15mg/day and the remaining two reached
10mg/day. Treatment adherence was >95% for all
patients.
The conventional MR brain parenchyma images
were normal in all subjects. The mean values of the
metabolite ratios, the absolute value and the correlation
coefficient are shown in Table 1, reported by each
exploration area. Significant changes between baseline
and post-treatment metabolite levels were seen in all the
patients. After three months of memantine treatment,
the Glx/Cr ratio (the main outcome of the study)
increased in the anterior insula (2.03 vs 2.17; r¼ 0.71;
p¼ 0.022) and in the posterior insula (1.77 vs. 2.00;
r¼ 0.82; p¼ 0.004). There was a significant increase in
Cho/Cr in the posterior cingulate (0.18 at baseline vs.
0.19 after treatment; r¼ 0.71; p¼ 0.023); NAAþ
NAAG increased in the anterior insula (7.56 vs. 7.70;
r¼ 0.67; p¼ 0.033); NAA increased (4.47 at baseline vs.
4.71 after treatment; r¼ 0.75; p¼ 0.02) and NAA
NAAG also increased (5.89 vs. 5.98; r¼ 0.82;
p¼ 0.007) in the left hippocampus. In the right hippo-
campus, Cr increased (3.60 vs. 3.85; r¼ 0.82; p¼ 0.007)
and NAAþNAAG also increased (5.31 vs. 5.79;
r¼ 0.80; p¼ 0.01). There was a decrease in the Cho
(1.31 vs. 1.29, r¼ 0.83; p¼ 0.003) and Cho/Cr levels
in the posterior insula (0.24 vs. 0.23; r¼ 0.79;
p¼ 0.006), in Cho in the left hippocampus (1.43 vs.
1.42; r¼ 0.75; p¼ 0.020) and in the Cho/Cr ratio (0.34
vs. 0.33; r¼ 0.85; p¼ 0.004) in the right hippocampus at
baseline and again after three months of treatment with
memantine.
Table 2 summarises the clinical and psychological
outcomes of the study. At the three-month follow-up,
Table 1. Absolute values and creatine ratios of various metabolites in the posterior cingulate, right anterior
and posterior insula, and both hippocampi in 10 fibromyalgia patients before treatment and after three
months of treatment with memantine.
Region and metabolites
Baseline (N¼ 10) Post treatment (N¼ 10)
Correlation (r) p-Value*M (SD) M (SD)
Posterior cingulate
Cho/Cr 0.18 (0.02) 0.19 (0.04) 0.71 0.023
Anterior insula
NAAþNAAG 7.56 (0.68) 7.70 (0.81) 0.67 0.033
Glx/Cr 2.03 (0.27) 2.17 (0.34) 0.71 0.022
Posterior insula
Glx/Cr 1.77 (0.34) 2.00 (0.12) 0.82 0.004
Cho 1.31 (0.14) 1.29 (0.11) 0.83 0.003
Cho/Cr 0.24 (0.03) 0.23 (0.02) 0.79 0.006
Left hippocampus
NAA 4.47 (1.53) 4.71 (0.98) 0.75 0.020
NAAþNAAG 5.89 (1.12) 5.98 (1.29) 0.82 0.007
Cho 1.43 (0.18) 1.42 (0.25) 0.75 0.020
Right hippocampus
Cr 3.60 (0.79) 3.85 (0.71) 0.82 0.007
NAAþNAAG 5.31 (1.12) 5.79 (0.96) 0.80 0.010
Cho/Cr 0.34 (0.04) 0.33 (0.02) 0.85 0.004
*Non-parametric Wilcoxon’s test. Cho/Cr: choline/creatine ratio; NAA: N-acetylaspartate; NAAþNAAG: N-acetylaspartateþN-
acetylaspartyl-glutamate; Glx/Cr: glutamateþglutamate/creatine ratio.
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FM patients treated with memantine improved in cog-
nitive function. The patients were assessed with the
MEC (M¼ 31.50, SD¼ 2.95 at baseline vs. M¼ 34.40,
SD¼ 0.69 at three months; p¼ 0.005). Depression was
measured with the HADS-d (M¼ 7.70, SD¼ 0.81 at
baseline vs. M¼ 7.56, SD¼ 0.68 at three months;
p¼ 0.042), and clinical severity was assessed with the
CGI severity scale (M¼ 5.79, SD¼ 0.96 at baseline vs.
M¼ 5.31, SD¼ 1.12 at three months; p¼ 0.007).
There was no relationship between improvement and
the number of pills taken. There was also no relationship
between an improvement in psychological variables and
changes in any metabolite in any brain region.
Table 3 shows the correlation of brain metabolite
values and neuropsychological variables in individuals
with FM after treatment with memantine. After analys-
ing metabolites and their correlation with clinical vari-
ables, it was found that in the posterior cingulum,
Table 3. Correlation of brain metabolite values and neuropsychological variables in individuals with fibromyalgia after treatment with
memantine.
Variable Pain MEC HADS-a HADS-d FIQ CGI R2
Posterior cingulate
Cr –0.01 (0.001) 0.06 (0.0006) 0.38 (0.034) –0.14 (0.050) 95.89%
mI 0.02 (0.003) 0.06 (0.014) –0.017 (0.010) 88.95%
mI/Cr 0.01 (0.0004) –0.012 (0.003) –0.012 (0.0009) –0.016 (0.007) 0.073 (0.012) 97.13%
Cho 0.06 (0.001) –0.011 (0.003) 0.15 (0.030) 81.93%
Glx/Cr 0.11 (0.041) 42.08%
Anterior insula
Cr –0.11 (0.025) 72.22%
Cho 0.10 (0.020) –0.02 (0.007) 77.73%
Cho/Cr
tNAA –0.03 (0.010) 54.06%
Posterior insula
mI/Cr –0.07 (0.018) 0.09 (0.026) 67.77%
NAA 0.078 (0.028) –0.411 (0.188) 87.70%
NAA/Cr 0.010 (0.001) –0.10 (0.0006) 0.017 (0.0003) –0.14 (0.001) –0.001 (0.0002) 0.15 (0.0002) 99.98%
Cho 0.05 (0.001) 0.013 (0.004) –0.08 (0.021) –0.01 (0.002) 82.77%
Cho/Cr 0.001 (0.001) 0.003 (0.001) –0.02 (0.002) –0.002 (0.001) 0.013 (0.0004) 93.92%
Glx –0.13 (0.031) 59.92%
Glx/Cr 0.081 (0.028) –0.018 (0.004) 62.68%
Left hippocampus
Glu/Cr –0.054 (0.022) 56.43%
Cho/Cr –0.001 (0.001) 0.022 (0.0065) 58.03%
Cr: creatine; mI: myo-inositol; Cho: choline; tNAA: total N-acetylaspartateþN-acetylaspartate glutamate; Glx: glutamateþglutamine; Glu: glutamate; Glu/
Cr: glutamate/creatine ratio.
Table 2. Psychological outcomes at baseline and at three-month follow-up.
Baseline Three-month follow-up
Variable M SD M SD p
Pain VAS 54.00 24.92 48.00 26.99 0.504
Pain sphygmomanometer 86.00 30.62 104.00 50.81 0.165
HADS-a 11.50 3.97 10.20 3.58 0.408
HADS-d 7.70 0.81 7.56 0.68 0.042*
MEC 31.50 2.95 34.40 0.69 0.005*
CGI-Severity 5.79 0.96 5.31 1.12 0.007*
FIQ 58.95 17.48 49.81 20.52 0.202
EQ-5D 49.50 19.50 55.50 23.85 0.330
*Non-parametric Wilcoxon’s test: p<0.05. HADS: Hospital Anxiety Depression Scale; -a: anxiety; -d: depression; MEC:
Cognitive Mini-Exam; CGI-Severity: illness severity; FIQ: Fibromyalgia Impact Questionnaire; EQ-5D: EuroQol 5D
questionnaire.
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the increase in Cr had a significant negative correlation
with perceived pain and the CGI (increase in metabolite
and decrease in perceived pain and severity of symp-
toms), Cho augmentation had a negative correlation
with the FIQ, and mI/Cr augmentation had a signifi-
cant negative correlation with the MEC, HADS-a and
HADS-d. In the anterior insula, the increase in Glu has
significant negative correlation with the CGI, the incre-
ment of Cr and Cho had a negative correlation with
HADS-a and the increase in total NAA had a negative
correlation with perceived pain. In the posterior insula,
the increase of mI/Cr had a significant negative correl-
ation with HADS-d, the increase in NAA had a signifi-
cant negative correlation with the MEC and FIQ, the
increase in NAA/Cr had a significant negative correl-
ation with the MEC, HADS-d and FIQ, the increment
of Cho and Cho/Cr had a significant negative correl-
ation with the HADS-d and FIQ and the increase in
Glx and Glx/Cr had a significant negative correlation
with the FIQ. In the left hippocampus, the increase in
Cho/Cr had a significant negative correlation with per-
ceived pain.
Discussion
This study assessed the efficacy of memantine, a
NMDA receptor antagonist, in the treatment of FM.
The rationale for using memantine was the high levels
of Glu found in some brain regions of FM patients.28–30
We evaluated the effect of memantine both in brain
metabolites and in relevant clinical variables of FM
and explored the correlations existing between them.
This 1H-MRS study has four major findings between
baseline and three months post treatment in patients
who received memantine: (a) an increase in Glx/Cr in
the anterior and posterior insula, (b) raised levels of
NAA and NAAþNAAG in both hippocampi and the
anterior insula, (c) an increase in Cr in the right hippo-
campus and (d) reduced Cho in the posterior insula and
both hippocampi.
This study found an increase in the Glx/Cr ratio in
the anterior and posterior insula three months post
treatment (Figure 2).
Previous studies have showed Glu increases in the
posterior insula30 and left amygdale29 in FM patients
and increases in Glx/Cr levels in the PCC28 in patients
with FM and somatisation disorder.
Although the cause of FM remains inconclusive,
there are converging data in favour of a dysregulation
of pain processing in the CNS of FM patients, particu-
larly associated with an increase in cerebral Glu levels.
Furthermore, there is evidence to support an associ-
ation between increased Glu levels and an increase in
FM symptoms.45
A number of authors46,47 further support a causal
relationship between raised cerebral Glu and FM by
demonstrating reversibility. They show that treatment
of FM with acupuncture or pregabalin results in a
reduction in cerebral Glu levels compared to placebo.
Paradoxically, a previous study conducted by our
group in patients with FM who were treated with mem-
antine for six months showed an increase in cerebral
Glu, Glu/Cr and Glx in the posterior cingulate.
However, it has been postulated that this is due to the
mechanism of action of the drug, which acts as a recep-
tor antagonist that blocks the action of Glu rather than
reducing Glu levels.48 The mechanism of action would
not be a reduction in the levels of glutamate or its
Figure 2. Box plots representing the glutamateþglutamine/creatine ratios (Glx/Cr) in the posterior insula in fibromyalgia patients who
were treated with memantine for three months. Glx/Cr represents baseline values, whereas Glx/Cr2 represents post-treatment values.
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release. Instead, glutamine would reduce its neurotoxic
effect, stopping the entry of excess calcium as it blocks
the (NMDA) receptor.49
Mechanisms that might increase the combined Glx
(GluþGlnþGABA) concentration include greater pre-
synaptic vesicular release of Glu,50 faster breakdown
of NAAG into NAA and Glu,51 slower conversion of
Gln to GABA52 and net production rather than con-
sumption of Glu by the Krebs cycle in neurons and
astrocytes.53,54
It is known that synaptic Glu is taken up by astro-
cytes, where it is converted to Gln and transported to
neurons for the production of Glu or GABA.11,21 One
theory that has been postulated is that the observed
association between Glu levels in the brain and FM is
due to a deficiency in astrocyte activity,55 although it
has recently been postulated that pain in FM may be
related to glial activation rather than astrocytes.56 It
has generally been described that mean Glx and
GABA levels (pooled across regions of interest) corre-
lated positively, indicating that participants with higher
levels of Glx also show higher levels of GABA.57 The
reported 1H-MRS levels of Glx therefore reflect the
joint neurotransmitter pools, which may be related to
both signalling and metabolism.
FM and chronic pain are associated with abnormal-
ities in the levels of certain brain metabolites, including
decreases in NAA in both hippocampi,58,59 the dorso-
lateral prefrontal cortex60 and the thalamus61 and
decreases in NAAþNAAG in the hippocampus and
the posterior insula.28,62 The hippocampus plays a
role in memory and cognition,63 two functions that
may be influenced by prolonged stress. The posterior
insula is known to play a prominent role in pain and
interoceptive sensory processing,64 whereas the anterior
insula is involved in the affective processing of pain and
other subjective feelings.65
We found an increase in NAA and NAAþNAAG
levels in both hippocampi and the anterior insula of
patients after three months of treatment with meman-
tine compared to the baseline study. NAA is a marker
of neuronal density/dysfunction, axonal viability and
mitochondrial metabolism.66 The function of NAA
within axons in the white matter is unknown, but one
of its roles may involve the synthesis of neurotransmit-
ters.67 There are two reports indicating that postnatal
membrane turnover is high with increasing brain con-
centrations of NAA, Cr and PCr.68,69 The responsive-
ness of NAA to improved neuron ‘health’ suggests
similar measures of NAA as a potential surrogate
for therapeutic efficacy in FM, and increased NAA
levels were detected under treatment with memantine
(Figure 3). NAAG is co-localised with NAA in neurons
and releases NAA and Glu when it is cleaved by
N-acetylated alpha-linked dipeptidase.70 Glu, and pos-
sibly NAAG, are excitatory amino acids. Within
physiological concentrations, Glu can be neurotoxic.
Data suggest that NAAG may be the form in which
the neuron stores Glu in order to protect the cell from
the compound’s excitatory, and potentially neurotoxic,
action. The quantification of NAA by 1H-MRS could
improve understanding of other neurological condi-
tions. For example, lower hippocampal NAA levels
suggest a neuronal or an axonal metabolic dysfunction
or a combination of these processes. Some studies
found that the persistence of elevated Ca2þ levels in
hippocampal neurons exposed to Glu correlated with
the extent of neuronal death71 and that a large increase
Figure 3. Box plots representing N-acetylaspartate in the left hippocampus in fibromyalgia patients who were treated with memantine
for three months. NAA represents baseline values, whereas NAA2 represents the post-treatment values.
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in Ca2þ in cultured hippocampal neurons after Glu
application predicted cell death.72 We suggest that hip-
pocampal dysfunction may be partially responsible for
some of the phenomena associated with FM. Blocking
NMDA receptors in the hippocampal formation
reduces nociceptive behaviours. This in turn supports
the hypothesis that the hippocampal formation is
involved in pain-related neural processing and the
expression of pain-related behaviours.73 Memantine
acts as a neuroprotectant by decreasing Glu excitotoxi-
city, and it is known to increase levels of brain-derived
neurotrophic factor, thus influencing synaptic plasticity
in rats and reducing beta-amyloid-induced apoptotic
death and neuroinflammation in the hippocampus.74
We found a significant elevation of creatine/
phosphocreatine in the right hippocampus, and a stat-
istically insignificant elevation in the posterior, anterior
and posterior insula post treatment. Creatine is taken in
the diet, and in humans, it is synthesised within the
liver, kidneys and pancreas. Cr and PCr are measured
as a single peak with 1H-MRS. PCr serve as a reserve
for high-energy phosphates in the cytosol of muscle and
neurons and buffers cellular adenosine triphosphate/
adenosine diphosphate (ATP/ADP) reservoirs. Tissues
such as muscle and brain where the largest changes in
energy metabolism occur have the highest concentra-
tions of creatine kinase enzyme. Cr is used as internal
reference value, as it is the most stable brain metabolite.
It has a role in the brain’s energy supply system and in
osmoregulation.36
We found a decrease in Cho and Cho/Cr ratios in
the posterior insula and both hippocampi post treat-
ment with memantine compared to baseline metabol-
ites. This was caused both by a decrease in Cho and by
a significant increase in Cr. Previous studies have
shown an increase in Cho/Cr in the caudate nucleus
and ventrolateral prefrontal cortex of patients with
FM compared to healthy controls.28 Cho is the precur-
sor for acetylcholine (ACho) and phosphatidylcholine
(PtdCho). The synthesis of ACho occurs only within
cholinergic neurons, whereas all cells use Cho to syn-
thesise PtdCho, which is a major constituent of the
cell membrane.75 Cho is a marker of phospholipid
metabolism a marker of cellular membrane turnover,
reflecting cellular proliferation. Membrane synthesis,
however, is an active process, suggesting that Cho
levels may also reflect cell energetic status.76 Changes
in Cho/Cr levels (though non-specific) do provide a
sensitive indication of altered brain metabolic activity.
The exact pathophysiology that could explain altered
Cho/Cr levels in FM is unclear.28 We also found an
increase in Cho/Cr in the posterior cingulate of three
patients. One hypothesis would be that the second
voxel was placed very close to the corpus callosum,
which may have altered the values, given that the
white matter contains a higher amount of Cho than
the grey matter.
In our study, memantine improved several key clin-
ical aspects of FM: cognitive function, depression and
overall clinical symptoms. Despite the cognitive dys-
function characteristics of FM,77 it is quite different
from that of dementia. The effectiveness of memantine
in dementia78 would lead one also to expect a positive
effect on FM. The improvement in depression is more
unexpected. Some preliminary reports have described
rapid antidepressant effects in treatment-resistant
bipolar depression after an intravenous infusion of
ketamine, another NMDA receptor antagonist.79
However, this is the first time in which a three-month
follow-up antidepressant effect has been demonstrated
with an NMDA receptor antagonist using oral treat-
ment. In addition to its effect on FM, memantine
could possibly be assessed as an add-on treatment for
treatment-resistant depression. Previous studies con-
ducted by our research group with patients treated
for six months with memantine showed a correlation
between the Cho and the FIQ in the posterior insula.66
The memantine significantly decreased ratings on a
pain VAS and pain measured with a sphygmomanom-
eter. All other secondary outcomes, except anxiety, also
improved.80
Finally, an improvement in overall clinical symptoms
may be foreseen because of the rationale of this study:
the raised Glu levels described in FM patients28–30 and
possibly related to pain and other FM symptoms were
supposed to be decreased by an NMDA receptor antag-
onist. This result has been demonstrated, and we have
seen how the clinical improvement of some neuropsy-
chological variables correlates with metabolic changes.
Therefore, longer follow-ups are necessary to confirm
the time stability of the improvement produced with
memantine.
Limitations
These results should be considered with caution due to
some important limitations of this study. This is not a
controlled study, and the sample size is small because of
its exploratory nature.
Conclusions
This pilot study has shown that memantine demon-
strated spectroscopic effects in patients with FM. Our
results demonstrate raised neuronal and axonal meta-
bolic function, or a combination of these processes,
supporting the hypothesis that memantine may induce
some short-term recovery of neuronal function in brain
regions significantly affected by FM. MRS could be
useful in monitoring the progress of and response to
FM treatment.
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